Cost-effectiveness of Low-density Lipoprotein Cholesterol Level–Guided Statin Treatment in Patients With Borderline Cardiovascular Risk

Authors:

Abstract
Hydroxymethylglutaryl–coenzyme A reductase inhibitors (statins) reduce low-density lipoprotein cholesterol (LDL-C) levels and are a cornerstone of primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD).1-5 Recent cholesterol treatment guidelines recommended selecting patients for statin treatment based on predicted 10-year absolute risk (AR10) of ASCVD.6,7 In addition to recommending primary prevention statin treatment for adults with diabetes and LDL-C levels of at least 190 mg/dL (to convert to millimoles per liter, multiply by 0.0259), the 2013 American College of Cardiology/American Heart Association (ACC/AHA) guideline recommended statins in adults with AR10 of at least 7.5%.6 A 2018 ACC/AHA update suggested statins be considered for primary prevention in patients without diabetes and with borderline AR10 (5.0%-7.4%) if the patients have risk-enhancing factors.2 Among those risk-enhancing factors is an LDL-C level of at least 160 mg/dL.

This publication has 33 references indexed in Scilit: